In addition to potential direct effects on tumor cells, PPARγ agonists have also been shown to suppress cellular signaling pathways that are associated with the production of many inflammatory cytokines and chemokines that can recruit and activate cells of the immune system [5,16,17]. Here, PPARG is linked to neoplasm.